



OPEN ACCESS

APPROVED BY
Journal of Pharmacy & Pharmaceutical
Sciences Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Seulah Lee,
✉ lee.seulah@khu.ac.kr

RECEIVED 10 September 2025
REVISED 29 October 2025
ACCEPTED 30 January 2026
PUBLISHED 17 February 2026

CITATION
Kwon S, Jeong S and Lee S (2026)
Corrigendum: Optimized *Ginkgo biloba*
extract EGb 761[®]: boosted therapeutic
benefits with minimized CYP
enzyme interference.
J. Pharm. Pharm. Sci. 29:15563.
doi: 10.3389/jpps.2026.15563

COPYRIGHT
© 2026 Kwon, Jeong and Lee. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Corrigendum: Optimized *Ginkgo biloba* extract EGb 761[®]: boosted therapeutic benefits with minimized CYP enzyme interference

Sunbeom Kwon^{1,2}, Suji Jeong^{1,2} and Seulah Lee^{1,2*}

¹Department of Convergent Biotechnology and Advanced Materials Science, College of Life Sciences, Kyung Hee University, Yongin, Republic of Korea, ²BK21 Interdisciplinary Program in IT-Bio Convergence System, Kyung Hee University, Yongin, Republic of Korea

KEYWORDS

EGb 761[®], protocatechuic acid, cognitive enhancement, molecular docking, CYP inhibition

A Corrigendum on
Optimized *Ginkgo biloba* extract EGb 761[®]: boosted therapeutic benefits with minimized CYP enzyme interference

by Kwon S, Jeong S and Lee S (2025). *J. pharm. pharm. Sci.* 28:14614. doi: 10.3389/jpps.2025.14614

In the published article, references 27 and 28 were cited in the **Conclusion** section. Due to the text correction listed below, these citations have been removed.

In the published article, there is an erroneous statement in the **Conclusion** section: “The potential inhibitory effects of PCA on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 have been reported based on molecular docking simulations [27]. In particular, *in vivo* animal studies have demonstrated that PCA inhibits the enzymatic activity of CYP1A2 and CYP2E1 [28]. On the basis of prior research, it is reasonable to hypothesize that the enhanced CYP inhibition observed in EGb 761[®], A4, and B2 is associated with their high concentrations of PCA.”

The correct statement is “While a direct causal relationship between reduced CYP inhibitory activity and PCA could not be definitively confirmed—due to the presence of numerous other compounds in EGb 761[®] and other raw materials or final drug products—further research is needed to clarify this relationship, as the chemical composition of *G. biloba* extracts is well-documented.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.